

**Jun 20, 2025**

To Whom It May Concern,

I have founded the departments of cancer and of HIV/AIDS at Harvard Medical School, as well as Human Genome Sciences and several biotechnology companies, including Cambridge Biosciences, The Virus Research Institute, ProScript, LeukoSite, Dendreon, Diversa, X-VAX, and Demetrix.


I joined the Scientific Advisory Board of Libera Bio at the end of 2024. As an observer of and author on new medical technologies, I am convinced that nanodelivery technologies will be increasingly essential for novel treatments. The MPN Technology®, consisting of nanocapsules versatile enough to carry antibodies, RNA, small molecules, and more, is very promising and has accumulated compelling evidence in preclinical models, in oncology, hepatology, and other areas.

The company was formed in 2020. Its CSO is Professor María José Alonso, an alum of the Langer Lab and an expert in drug delivery, recognized by multiple awards and scientific associations. Co-founders Olivier Jarry, CEO, and Desirée Teijeiro, PhD, CSO, bring decades of pharmacological development and business experience.

Their business model includes building alliances with biopharma companies that have difficult delivery problems to solve, and has already resulted in half a dozen alliances.

I believe the company may make a strong impact in the coming years and bring to patients a series of new treatments for difficult-to-treat diseases such as those associated with dysfunctional intracellular pathways.

With best regards,



William A. Haseltine  
Chair, ACCESS Health International  
Professor, The Feinstein Institute for Medical Research  
<https://williamhaseltine.com/>